



# **Evaluation of Microneedling With or Without Topical 5-fluorouracil in Treatment of Stable Non- segmental Vitiligo**

*Thesis*

*Submitted for Partial Fulfillment of Master Degree  
In Dermatology, Venereology & Andrology*

*By*

**Fedaa Ezzat Soliman**

*M.B.B.CH*

**Under supervision of**

**Prof. Dr. Naziha Hafez Khafagy**

*Professor and Head of Dermatology, Venereology and  
Andrology Department*

*Faculty of Medicine, Ain-Shams University*

**Dr. Samah Ibrahim Hasssan**

*Lecturer of Dermatology, Venereology and Andrology*

*Faculty of Medicine, Ain-Shams University*

*Faculty of Medicine  
Ain Shams University*

*2020*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قَالَ

لَسْبَدَانِكَ لَا مَلِم لِنَا  
إِلَّا مَا مَلِمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدقة الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,  
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Maziha Hafez Khafagy**, Professor and Head of Dermatology, Venereology and Andrology Department Faculty of Medicine, Ain-Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Samah Ibrahim Hassan**, Lecturer of Dermatology, Venereology and Andrology Faculty of Medicine, Ain-Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*Fedaa Ezzat*

# *List of Contents*

| <b>Title</b>                | <b>Page No.</b> |
|-----------------------------|-----------------|
| List of Abbreviations ..... | i               |
| List of Tables .....        | iv              |
| List of Figures .....       | v               |
| Introduction .....          | 1               |
| Aim of the Work .....       | 4               |
| Review of Literature        |                 |
| Overview of Vitiligo.....   | 5               |
| 5-Fluorouracil .....        | 50              |
| Patients and Methods .....  | 67              |
| Results .....               | 74              |
| Case presentation .....     | 84              |
| Discussion .....            | 96              |
| Summary .....               | 108             |
| Conclusion.....             | 111             |
| Recommendations.....        | 112             |
| References .....            | 113             |
| Arabic Summary .....        | —               |

# *List of Abbreviations*

| Abb.                | Full term                            |
|---------------------|--------------------------------------|
| 5-FU.....           | 5-Fluorouracil                       |
| 5-FUH2 .....        | 5-Fluoro dihydrouracil               |
| AKs .....           | Actinic keratoses                    |
| BB-UVB .....        | Broad Band Ultraviolet B             |
| BCC .....           | Basal cell carcinomas                |
| BSA.....            | Body surface area                    |
| CL.....             | Cardiolipin                          |
| CRC .....           | Colorectal cancer                    |
| CTLA4.....          | Cytotoxic T lymphocytic antigen 4    |
| DNA.....            | Deoxyribonucleic acid                |
| DOPA .....          | Dihydro phenylalanine                |
| DPD .....           | Dihydro pyrimidine dehydrogenase.    |
| DRS .....           | Diffuse reflectance spectroscopy     |
| dTMP.....           | Deoxythymidine mono-phosphate        |
| dUMP .....          | Deoxyuridine mono-phosphate          |
| Ecad.....           | E-cadherin                           |
| ECG .....           | Electrocardiography                  |
| ER.....             | Endoplasmic reticulum                |
| ER-YAG .....        | Erbium: yttrium-aluminum-garnet      |
| FdUMP.....          | Fluorodeoxyuridine monophosphate     |
| FdUTP.....          | Fluorodeoxyuridine triphosphate      |
| FUTP.....           | Fluorouridine triphosphate           |
| GTP .....           | Guanisine triphosphate               |
| H2O2 .....          | Hydrogen peroxide                    |
| HLA-DR .....        | Human leukocyte antigen- DR [HLA-DR] |
| HMB45.....          | Melanoma monoclonal antibody         |
| HPV .....           | Human papillomavirus                 |
| ID .....            | Intradermal injection                |
| IFN- $\gamma$ ..... | Interferon gamma                     |
| IL .....            | Interleukin                          |

## *List of Abbreviations Cont...*

| <b>Abb.</b> | <b>Full term</b>                         |
|-------------|--|
| KA.....     | Keratoacanthoma                          |
| KP .....    | Koebner phenomenon                       |
| KUVA.....   | Khellin and ultraviolet A                |
| LTC4 .....  | Leukotriene C4                           |
| LTD4 .....  | Leukotriene D4                           |
| MART .....  | Melanoma Antigen Recognized by T cells   |
| MBEH .....  | Monobenzyl ether of hydroquinone         |
| MCHR .....  | Melanin-concentrating hormone receptor   |
| MITF .....  | Melanocyte inducing transcription factor |
| MKTP .....  | Melanocyte keratinocyte transplantation  |
| MOP .....   | Methoxypsoralen                          |
| MP .....    | Methoxyphenol                            |
| NBUVB.....  | Narrow Band Ultraviolet B                |
| NCECS.....  | Non cultural epidermal cell suspension   |
| NGF.....    | Nerve growth factors                     |
| NMSC.....   | Nonmelanoma skin cancer                  |
| NPY .....   | Neuropeptide Y                           |
| NSV .....   | Non segmental vitiligo                   |
| PASI .....  | Psoriasis Area and Severity Index        |
| PG.....     | Punch grafting                           |
| PUVA .....  | Psoralen and ultraviolet A               |
| QSR .....   | Q-switched ruby laser                    |
| RCM .....   | Reflectance confocal microscopy          |
| RNA.....    | Ribonucleic acid                         |
| ROS .....   | Reactive oxygen species                  |
| SBEG.....   | Suction blister epidermal grafting       |
| SCC.....    | Squamous cell carcinoma                  |
| STDS .....  | Sexual transmitted diseases              |
| SV .....    | Segmental vitiligo                       |

## *List of Abbreviations Cont...*

| <b>Abb.</b>        | <b>Full term</b>                        |
|--------------------|---|
| T reg .....        | Regulatory T cells                      |
| TFH .....          | Follicular Helper T cell                |
| TGF- $\beta$ ..... | Transforming growth factor B            |
| Th.....            | T helper cells                          |
| TH.....            | Tyrosine hydroxylase                    |
| TNF .....          | Tumor necrosis factor                   |
| TRP.....           | Tyrosine related protein                |
| TS.....            | Thymidylate synthetase                  |
| UTP .....          | Uridine triphosphate                    |
| UVA.....           | Ultraviolet A                           |
| UVB.....           | Ultraviolet B                           |
| UVR.....           | Ultraviolet radiation                   |
| VASI.....          | Vitiligo Area Scoring Index             |
| VESTA .....        | Vitiligo Extent Score for a Target Area |
| VETF .....         | Vitiligo European Task Force            |
| VETI.....          | Vitiligo Extent Tensity Index           |
| VIDA.....          | Vitiligo disease activity score         |

# *List of Tables*

| Table No.          | Title   | Page No. |
|--------------------|---|----------|
| <b>Table (1):</b>  | Classification of vitiligo .....  | 19       |
| <b>Table (2):</b>  | Distribution of vitiligo cases according to demographic and clinical data .....   | 75       |
| <b>Table (3):</b>  | Distribution of vitiligo cases according to Fitzpatrick skin phototype .....  | 76       |
| <b>Table (4):</b>  | Distribution of vitiligo cases according to site of lesion.....   | 77       |
| <b>Table (5):</b>  | Comparison of the response to treatment between microneedling side only and microneedling with 5-FU side.....   | 78       |
| <b>Table (6):</b>  | Distribution of vitiligo cases according to percentage of repigmentation in microneedling with 5FU side.....  | 79       |
| <b>Table (7):</b>  | Distribution of the repigmented vitiligo cases according to pattern of repigmentation in microneedling with 5-FU side.....  | 80       |
| <b>Table (8):</b>  | Comparison of side effects between microneedling side only and microneedling with 5-FU side.....  | 81       |
| <b>Table (9):</b>  | Relation between the outcome (repigmentation) in microneedling with 5FU side and age, gender, VASI vitiligo score, Fitzpatrick skin phototype, family history and disease duration..... | 82       |
| <b>Table (10):</b> | Relation between outcome (repigmentation) in microneedling with 5FU side and lesion site.....   | 83       |

## *List of Figures*

| Fig. No.            | Title  | Page No. |
|---------------------|--|----------|
| <b>Figure (1):</b>  | 5-Flourouracil structure.....  | 50       |
| <b>Figure (2):</b>  | 5-Flourouracil metabolism.....   | 52       |
| <b>Figure (3):</b>  | Structure of 5-Flourouracil and Uracil.....  | 53       |
| <b>Figure (4):</b>  | Effect of 5-Flourouracil on DNA.....   | 54       |
| <b>Figure (5):</b>  | VESTA reference images of marginal and perifollicular repigmentation .....   | 72       |
| <b>Figure (6):</b>  | Formula for calculation of total repigmentation rate .....   | 72       |
| <b>Figure (7):</b>  | Bar chart distribution of vitiligo cases according to Fitzpatrick skin phototype. ....   | 76       |
| <b>Figure (8):</b>  | Bar chart distribution of vitiligo cases according to site of lesion. ....   | 77       |
| <b>Figure (9):</b>  | Bar chart between microneedling side only and microneedling with 5-FU side according to response to treatment. ....  | 78       |
| <b>Figure (10):</b> | Pie chart distribution of vitiligo cases in microneedling with 5FU side according to percentage of repigmentation.....   | 79       |
| <b>Figure (11):</b> | Bar chart distribution of vitiligo cases in microneedling with 5-FU side according to pattern of repigmentation. ....  | 80       |
| <b>Figure (12):</b> | Side effects in microneedling side only and microneedling with 5-FU side. ....   | 81       |
| <b>Figure (13):</b> | (A) vitiligo lesion in the upper limb before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing mild response (repigmentation less than 25%). .... | 84       |

## *List of Figures Cont...*

| Fig. No.            | Title   | Page No. |
|---------------------|---|----------|
| <b>Figure (14):</b> | (A) vitiligo lesion in the upper limb before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing mild response (repigmentation less than 25%)..... | 85       |
| <b>Figure (15):</b> | (A) vitiligo lesion in the lower limb before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing mild response (repigmentation less than 25%)..... | 86       |
| <b>Figure (16):</b> | (A) vitiligo lesion in the lower limb before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing mild response (repigmentation less than 25%)..... | 87       |
| <b>Figure (17):</b> | (A) vitiligo lesion in the trunk before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing mild response (repigmentation less than 25%).....      | 88       |
| <b>Figure (18):</b> | (A) vitiligo lesion in the face before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing mild response (repigmentation less than 25%).....       | 89       |
| <b>Figure (19):</b> | (A) vitiligo lesion in the neck before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing mild response (repigmentation less than 25%).....       | 90       |

## *List of Figures Cont...*

| <b>Fig. No.</b>     | <b>Title</b>   | <b>Page No.</b> |
|---------------------|--|-----------------|
| <b>Figure (20):</b> | (A) vitiligo lesion in the trunk before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing moderate response (repigmentation 25-50 %)      | 91              |
| <b>Figure (21):</b> | (A) vitiligo lesion in the upper limb before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing moderate response (repigmentation 25-50 %) | 92              |
| <b>Figure (22):</b> | (A) vitiligo lesion in the upper limb before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing moderate response (repigmentation 25-50 %) | 93              |
| <b>Figure (23):</b> | (A) vitiligo lesion in the upper limb before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing moderate response (repigmentation 25-50 %) | 94              |
| <b>Figure (24):</b> | (A) vitiligo lesion in the lower limb before treatment, (B) after the lesion was treated by (microneedling & 5-FU) for six sessions showing moderate response (repigmentation 25-50 %) | 95              |

## ABSTRACT

**Background:** This study will evaluate the effect of microneedling of vitiligo lesion with and without topical 5 fluorouracil. Vitiligo is an acquired pigmentary disorder of unknown etiology, affecting approximately 1 % of the world population, without predilection for race or sex. It is characterized by white macules and patches, whose size increases over time, due to the loss of melanocytes. Vitiligo can appear at any time, and it significantly impairs the patients' quality-of-life

**Objective:** To compare the efficacy of microneedling followed by 5-FU with microneedling alone in the treatment of stable non-segmental vitiligo.

**Patients and Methods:** This interventional study was held in Dermatology, Andrology & STDs department, Faculty of Medicine, Ain Shams University during the period from January till November 2019. Fifty patients with stable non-segmental vitiligo were included in the study.

**Results:** Regarding the efficacy of treatment with microneedling only vs microneedling with 5-FU in our study, there is statistically significant difference between the two sides according to treatment response, needling with 5-FU side showed response in 76% of cases, while needling side alone showed (0%) response. The degree of improvement among our patients in microneedling with 5-FU side, we detect different grades of repigmentation as 12 patients of the studied participants (24%) showed no repigmentation, 23 patients (46%) showed mild grade (<25% repigmentation), 15 patients (30%) showed moderate grade (25–50% repigmentation) and no one of the studied participants experienced either good grade (50–75% repigmentation) either excellent grade (more than

75% repigmentation). Our study showed no relation between repigmentation response and both demographic and clinical data of the patients as (age, gender, family history, duration of disease, VASI severity score and Fitzpatrick skin phototype). On the other hand, we found statistically significant difference with better repigmentation after microneedling with 5FU on certain sites of vitiligo. We noticed that lesions on the trunk and extremities showed better results while the acral parts showed no response. Observing side effects after treatment, we noticed that, there is statistically significant difference in side effects incidence between two sides. Side treated with microneedling and 5-FU experienced more frequent side effects as compared with the side treated with microneedling only, these side effects included, slight to moderate pain and burning sensation during procedure that was tolerated and disappeared within few minutes to hours and minimal erythema in the first few days post procedure.

**Conclusion:** On the basis of the current study, we can conclude that microneedling followed by topical 5% 5-FU of vitiligo lesion is safe and tolerable method of treatment of vitiligo. It can induce repigmentation in vitiligo lesion but it could not be considered as effective method of treatment. We need to combined it with other treatment modalities to improve the outcome. However, long follow-up of the patients is needed.

**Keywords:** 5-Flourouracil, vitiligo, microneedling

# INTRODUCTION

Vitiligo, the most common depigmented disorder, is an acquired disease characterized by progressive loss of melanocytes. Vitiligo occurs worldwide with an estimated prevalence of 0.5-1% in most populations and no sexual predominance. In 50% of cases, lesions develop before the age of 20 years and a familial susceptibility has been described (*Lotti et al., 2019*).

Clinically, vitiligo characterized by patchy depigmentation, the disease is frequently associated with cosmetic disfigurement and considerable psychological distress. The primary pathophysiological causes for the loss of functioning melanocytes include genetic predisposition, autoimmune mechanisms and oxidative stress (*Bleuel & Eberlein, 2018*).

Several treatment modalities are available and new ones are being developed. Treatments for vitiligo include topical agents, phototherapy-photochemotherapy, as well as systemic and surgical options. Topical agents, such as steroids and calcineurin inhibitors, are preferred particularly for restricted lesions, while phototherapy-photochemotherapy is preferred for patients with diffuse involvement. Mini-pulse systemic steroid treatment is used for patients with rapidly progressive disease (*Relke & Gooderham, 2019*).

Surgical are proposed as a therapeutic option in patients with segmental vitiligo, in which lesions tend to be stable, focal and medical therapies fail to induce repigmentation (*Dillon et al., 2017*).

5-Flourouracil (5-FU) is an antimetabolite analogue of the naturally occurring pyrimidine uracil. It is metabolized via the same metabolic pathways as uracil. Due to its antimitotic activity, it is easy to understand that topical 5-FU is a useful therapy for the treatment of many dermatological disorders characterized by a high mitotic rate (e.g., nonmelanoma skin cancers, actinic keratosis, benign tumours, nail psoriasis, and porokeratosis) (*Sachs et al., 2009; Desai et al., 2012*).

Clinically, localized hyperpigmentations have been reported during systemic treatment of various cancers by 5-FU. Usually, these hyperpigmented lesions are located on the normally pigmented extremities (hands and feet) and tongue. It has been postulated that these hyperpigmentations could be considered as postinflammatory hyperpigmentations on sites submitted to repeated friction (*Chan & Lin, 2010*).

Microneedling-assisted drug delivery (MADD) involves the use of microneedles to generate microchannels through which a drug can diffuse to enhance the transdermal delivery, other techniques include curettage, dermabrasion, pressure waves, vacuum, and radiofrequency, by using these modalities many of medications have been successfully delivered